BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

...for antiviral activity. Repurposing candidates include at least two that inhibit BRD2/BRD4: apabetalone (RVX-208) from Resverlogix Corp....
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...and Complexa Inc. has CXA-10, which also regulates NF-κB, in Phase II for renal damage. Resverlogix Corp....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Bardoxolone methyl Treat chronic kidney disease (CKD) caused by Alport syndrome Phase III data 2H19 Resverlogix Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...2H19 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Talicia (RHB-105) Helicobacter pylori infection Submit NDA 1H19 Resverlogix Corp....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

.../ Novartis AG (NYSE:NVS; SIX:NOVN) AVXS-101 Spinal muscular atrophy (SMA) type 1 Submit BLA 2H18 Resverlogix Corp....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NYSE:SNY) Cemiplimab Cutaneous squamous cell carcinoma Complete rolling BLA 1Q18 Resverlogix Corp....
BioCentury | Oct 20, 2017
Financial News

Resverlogix raises C$87M in private placement

...On Oct. 13, Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested...
...0.08 of a share. Prior to the placement, Hepalink held a 13% equity stake in Resverlogix...
...disease (ESRD) by year end (see BioCentury, May 4, 2015 ). Resverlogix Corp. (TSX:RVX), Calgary, Alberta Allison Johnson apabetalone RVX-208 RVX000222 Resverlogix Corp. Shenzhen...
BioCentury | Oct 13, 2017
Financial News

Shenzhen Hepalink triples stake in Resverlogix

...0.08 of a share. Prior to the placement, Hepalink held a 13% equity stake in Resverlogix...
...would have held a 14% stake. The new offering gives Hepalink a 43% stake in Resverlogix...
...BioCentury Extra, April 27, 2015) . Resverlogix lost C$0.20 (11%) to C$1.56 on Friday. Jaime De Leon apabetalone RVX-208 RVX000222 Resverlogix Corp. Shenzhen...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Alzheimer’s disease, and more than ten other companies are testing pan-HDAC inhibitors in non-oncology indications. Resverlogix Corp....
...Inc. (NYSE:PFE), New York, N.Y. Quimatryx S.L., San Sebastian, Spain Regenacy Pharmaceuticals LLC, Boston, Mass. Resverlogix Corp....
BioCentury | Jul 7, 2017
Clinical News

DSMB recommends fourth continuation of Phase III BETonMACE trial of apabetalone

...is an inhibitor of the BET family of bromodomain-containing proteins, including bromodomain containing 4 (BRD4). Resverlogix Corp....
...in lipid concentrations Status: Phase III ongoing Milestone: Complete Phase III enrollment (year end 2017) Julian Zhu apabetalone RVX-208 RVX000222 Resverlogix Corp. Apolipoprotein...
Items per page:
1 - 10 of 114
BioCentury | Mar 25, 2020
Product Development

Repurposing candidates for COVID-19 from UCSF, Aldeyra

...for antiviral activity. Repurposing candidates include at least two that inhibit BRD2/BRD4: apabetalone (RVX-208) from Resverlogix Corp....
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...and Complexa Inc. has CXA-10, which also regulates NF-κB, in Phase II for renal damage. Resverlogix Corp....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Bardoxolone methyl Treat chronic kidney disease (CKD) caused by Alport syndrome Phase III data 2H19 Resverlogix Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...2H19 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Talicia (RHB-105) Helicobacter pylori infection Submit NDA 1H19 Resverlogix Corp....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

.../ Novartis AG (NYSE:NVS; SIX:NOVN) AVXS-101 Spinal muscular atrophy (SMA) type 1 Submit BLA 2H18 Resverlogix Corp....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Inc. (NASDAQ:REGN) / Sanofi (Euronext:SAN; NYSE:SNY) Cemiplimab Cutaneous squamous cell carcinoma Complete rolling BLA 1Q18 Resverlogix Corp....
BioCentury | Oct 20, 2017
Financial News

Resverlogix raises C$87M in private placement

...On Oct. 13, Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested...
...0.08 of a share. Prior to the placement, Hepalink held a 13% equity stake in Resverlogix...
...disease (ESRD) by year end (see BioCentury, May 4, 2015 ). Resverlogix Corp. (TSX:RVX), Calgary, Alberta Allison Johnson apabetalone RVX-208 RVX000222 Resverlogix Corp. Shenzhen...
BioCentury | Oct 13, 2017
Financial News

Shenzhen Hepalink triples stake in Resverlogix

...0.08 of a share. Prior to the placement, Hepalink held a 13% equity stake in Resverlogix...
...would have held a 14% stake. The new offering gives Hepalink a 43% stake in Resverlogix...
...BioCentury Extra, April 27, 2015) . Resverlogix lost C$0.20 (11%) to C$1.56 on Friday. Jaime De Leon apabetalone RVX-208 RVX000222 Resverlogix Corp. Shenzhen...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Alzheimer’s disease, and more than ten other companies are testing pan-HDAC inhibitors in non-oncology indications. Resverlogix Corp....
...Inc. (NYSE:PFE), New York, N.Y. Quimatryx S.L., San Sebastian, Spain Regenacy Pharmaceuticals LLC, Boston, Mass. Resverlogix Corp....
BioCentury | Jul 7, 2017
Clinical News

DSMB recommends fourth continuation of Phase III BETonMACE trial of apabetalone

...is an inhibitor of the BET family of bromodomain-containing proteins, including bromodomain containing 4 (BRD4). Resverlogix Corp....
...in lipid concentrations Status: Phase III ongoing Milestone: Complete Phase III enrollment (year end 2017) Julian Zhu apabetalone RVX-208 RVX000222 Resverlogix Corp. Apolipoprotein...
Items per page:
1 - 10 of 114